| [1] | Monto A.S., Ansaldi F., Aspinall R., et al. (2009). Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27:5043−53. DOI:10.1016/j.vaccine.2009.06.032 |
| [2] | Goodwin K., Viboud C. and Simonsen L. (2006). Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 24:1159−1169. DOI:10.1016/j.vaccine.2005.08.105 |
| [3] | Falsey A.R., Treanor J.J., Tornieporth N., et al. (2009). Randomized, double-blind controlled phase III trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200:172−180. DOI:10.1086/599790 |
| [4] | Pardo-Seco J., Rodríguez-Tenreiro-Sánchez C., González-Melón L., et al. (2025). High-dose influenza vaccine to reduce hospitalizations. N. Engl. J. Med. 393:2303−2312. DOI:10.1056/NEJMoa2501234 |
| [5] | Johansen N.D., Modin D., Kjøller-Hansen L., et al. (2025). High-dose influenza vaccine effectiveness against hospitalization in older adults. N. Engl. J. Med. 393:2291−2302. DOI:10.1056/NEJMoa2501229 |
| Cai L., Hu X., Lin L., et al. (2026). High-dose influenza vaccination in older adults: Reconciling trial evidence for policy. The Innovation Medicine 4:100221. https://doi.org/10.59717/j.xinn-med.2026.100221 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Conceptual framework linking immunosenescence, trial evidence, and policy implications of high-dose influenza vaccination in older adults.